The November 30 PDUFA date for povetacicept in IgAN is the next major catalyst. Approval would establish Vertex's fifth commercial franchise in nephrology. Monitor the FDA decision and any label or pricing details, as well as Q4 revenue trajectory for CASGEVY and JOURNAVX to assess whether the raised guidance is conservative.
Drugs in focus
VRTX drug pipeline →povetacicept
▲ Bullish Named in this 8-K- Impact
- Phase
- Filed/PDUFA (BLA under FDA review for accelerated approval in IgAN); Phase 3 (RAINIER in IgAN); Phase 2b/3 (OLYMPUS in p
- Time to market
- PDUFA target action date of November 30, 2026 for accelerated approval in IgAN; if approved, launch could follow within weeks to months. Confirmatory Phase 3 data and potential pMN approval would follow in subsequent years.
- Next catalyst
- PDUFA date · Nov 30, 2026 13d
What to watchThe key binary event is the PDUFA date of November 30, 2026 for accelerated approval in IgA nephropathy. For Vertex, a diversified large-cap biotech, this is a pipeline-expansion catalyst rather than a make-or-break event, approval would open a new kidney-disease franchise, while a delay or CRL would be a setback but not existential. Watch for any FDA AdCom announcement and the BLA rolling submission completion before year-end.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $530.76entry
- T+1 · 13d ago +3.44%α +1.79% · $549.04
- T+5 · 7d ago +3.23%α +3.81% · $547.89
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vertex reported Q3 2026 total revenue of $3.44 billion, a 12% increase YoY, and raised full-year 2026 revenue guidance to $13.15-$13.25 billion. The quarter included the close of the $10B Crinetics acquisition and highlighted strong growth from non-CF products CASGEVY ($99M, +486% YoY) and JOURNAVX ($58M, +197% YoY), with a key near-term catalyst being the November 30 PDUFA date for povetacicept in IgAN.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue of $3.44 billion, up 12% YoY from $3.08 billion
- Full-year 2026 revenue guidance raised to $13.15-$13.25 billion from $13.1-$13.2 billion
- GAAP net income of $654 million, down from $1.08 billion YoY due to Crinetics acquisition costs
- CASGEVY revenue of $99 million, up 486% YoY and 30% QoQ
- JOURNAVX revenue of $58 million, up 197% YoY and 18% QoQ
- PALSONIFY contributed $10 million in first month post-Crinetics close
- Povetacicept BLA under FDA priority review with PDUFA date of November 30, 2026
- Completed acquisition of Crinetics Pharmaceuticals for $10 billion equity value
- Cash and marketable securities of $9.8 billion as of September 30, 2026
Financial Impact
Revenue guidance raised by $50M at midpoint; non-CF revenue (CASGEVY + JOURNAVX) on track to exceed $500M; PALSONIFY adding $40-50M
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| TRIKAFTA/KAFTRIO | $2.4B | -8.2% |
| ALYFTREK | $705.8M | +185.8% |
| Other CF products | $130.5M | -6.3% |
| CASGEVY | $99.2M | +487.0% |
| JOURNAVX | $58.3M | +197.4% |
| PALSONIFY | $10.1M | Not reported |
Risk Factors
- Povetacicept FDA decision on November 30 carries binary risk
- GAAP net income declined YoY due to acquisition-related expenses
- Integration of Crinetics and associated $4.5B in new debt increases leverage
- CF revenue growth dependent on continued ALYFTREK uptake and reimbursement expansion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000875320-26-000287 |
| Document: vrtx-20261102.htm | 0000875320-26-000287 |
| Document: 0000875320-26-000287-index-headers.html | 0000875320-26-000287 |
| Document: 0000875320-26-000287-index.html | 0000875320-26-000287 |
| Document: 0000875320-26-000287.txt | 0000875320-26-000287 |
| 8-K Data (Synthetic) | 0000875320-26-000287 |
Track record
21 reports on VRTX
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +10.87% at T+60 after the Feb 25, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
- Nov 16, 20261d ago 144 Neutral 2/10 Entry $543.10 Now $531.45 −2.15% settles Nov 23
- Nov 16, 20261d ago 144 Neutral 1/10 Entry $544.98 Now $531.45 −2.48% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $542.00 Now $531.45 −1.95% settles Nov 23
- Nov 12, 20265d ago 144 Neutral 2/10 Entry $542.62 Now $531.45 −2.06% settles Nov 19
- Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Viewing Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
- Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
- Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers